Approval of Tucatinib In Treatment of HER2+ Metastatic Breast Cancer

Approval of Tucatinib In Treatment of HER2+ Metastatic Breast Cancer

Episodes

Specialty:

All

Year:

All

EP. 1: Treatment for Metastatic Breast Cancer

ByRita Nanda, MD, The University of Chicago Medicine

July 1st 2020

EP. 2: A Close Look at Tucatinib in HER+ Breast Cancer

ByRita Nanda, MD, The University of Chicago Medicine

July 1st 2020

EP. 3: Understanding the HER2CLIMB Trial

ByRita Nanda, MD, The University of Chicago Medicine

July 1st 2020

EP. 4: The Benefits of Tucatinib in HER2+ Breast Cancer

ByRita Nanda, MD, The University of Chicago Medicine

July 1st 2020

Trending on OncLive

Intismeran Autogene Plus Pembrolizumab Meets RFS and DMFS End Points in Resected Stage IIB-IV Melanoma

ESMO Guidelines Express Update Recommends Daraxonrasib for RAS G12–Mutated Metastatic PDAC

Mo-Rez Advances Into Combination Studies Following Robust Responses in Gynecologic Cancers

mRNA Vaccines May Help Increase Long-Term Disease Control in PDAC

Harold P. Freeman, MD, Pioneer of Patient Navigation and Cancer Disparities Research, Dies at 93